Table 1.
Demographic description of the subjects
| Mean (CV%) | |||||||
|---|---|---|---|---|---|---|---|
| Study description | Race | n | Gender | Age, years | Weight (kg) | BMI (kg m−2) | CYP2D6 status |
| Single dose | Japanese | 24 | 14 Female 10 Male | 25 (20–31) | 58.7 (15.2) | 21.9 (9.6) | 17 EM, 6 IM, 1 PM |
| Single dose | Caucasian | 24 | 13 Female 11 Male | 25 (20–47) | 70.7 (15.5) | 24.2 (11.7) | 21 EM, 3 PM |
| Multiple doses | Japanese | 16* | 4 Female 12 Male | 23 (20–34) | 63.1 (9.2) | 22.2 (9.3) | 10 EM, 6 IM |
| Multiple doses | Caucasian | 16* | 5 Female 11 Male | 25 (19–48) | 72.5 (12.7) | 24.4 (9.3) | 15 EM, 1 UM |
Age shown as median (range).
*
Number of subjects assigned to active drug. CV, Coefficient of variation; UM, ultrarapid metabolizer; EM, extensive metabolizer; IM, intermediate metabolizer (reduced activity with CYP2D6 *10 genotype); PM, poor metabolizer.